title: Preoperative thrombocytosis predicts poor survival in patients with glioblastoma.
abstract: Thrombocytosis, which is defined as a platelet count greater than 400 platelets/nl, has been found to be an independent predictor of shorter survival in various tumors. Release of growth factors from tumors has been proposed to increase platelet counts. Preoperative platelet counts and other clinical and hematological parameters were reviewed from the records of 153 patients diagnosed between 1999 and 2004 with histologically confirmed glioblastoma in order to evaluate the prognostic significance of preoperative thrombocytosis in these patients. The relationship between thrombocytosis and survival was initially analyzed in all patients regardless of further therapy. Univariate log-rank tests showed that the median survival time of 29 patients with preoperative thrombocytosis (19%) was significantly shorter (4 months; 95% confidence interval [95% CI], 3-6 months) compared to 124 patients with normal platelet counts (11 months; 95% CI, 8-13 months; p = 0.0006). Multivariate analysis (Cox proportional hazards model) confirmed preoperative platelet count, age, prothrombin time, and activated partial thromboplastin time to be prognostic factors of survival (all p < 0.05). In a subset of patients (only operated patients with radiation therapy with or without additional chemotherapy), survival was likewise significantly shorter when preoperative thrombocytosis was diagnosed (6 months; 95% CI, 4-12 months) compared to patients with normal platelet count (13 months; 95% CI, 11-15 months; p = 0.0359). In multivariate analysis, age, platelet count, preoperative prothrombin time, and degree of tumor resection retained significance as prognostic factors of survival (all p < 0.05). The results of our study demonstrate preoperative thrombocytosis to be a prognostic factor associated with shorter survival time in patients with glioblastoma.
authors.affiliation: University Hospital Mannheim, Department of Neuroradiology, Theodor-Kutzer-ufer 1-3, 68167 Mannheim, Germany. brockmann@gmx.de
authors.forename: Marc A
authors.initials: MA
authors.lastname: Brockmann
authors.forename: Alf
authors.initials: A
authors.lastname: Giese
authors.forename: Kathrin
authors.initials: K
authors.lastname: Mueller
authors.forename: Finjap Janvier
authors.initials: FJ
authors.lastname: Kaba
authors.forename: Frank
authors.initials: F
authors.lastname: Lohr
authors.forename: Christel
authors.initials: C
authors.lastname: Weiss
authors.forename: Stefan
authors.initials: S
authors.lastname: Gottschalk
authors.forename: Ingo
authors.initials: I
authors.lastname: Nolte
authors.forename: Jan
authors.initials: J
authors.lastname: Leppert
authors.forename: Jochen
authors.initials: J
authors.lastname: Tuettenberg
authors.forename: Christoph
authors.initials: C
authors.lastname: Groden
mesh_terms: D000368:Aged; D001932:Brain Neoplasms / Q000150:complications* / Q000401:mortality* / Q000628:therapy; D005260:Female; D005909:Glioblastoma / Q000150:complications* / Q000401:mortality* / Q000628:therapy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures; D011379:Prognosis; D012189:Retrospective Studies; D013922:Thrombocytosis / Q000150:complications*